NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03520478,A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer,https://clinicaltrials.gov/study/NCT03520478,,ACTIVE_NOT_RECRUITING,The aim of this study is to compare the safety and efficacy of SHR3680 with bicalutamide in the treatment of patients with hormone sensitive prostate cancer.,NO,Prostate Cancer|Hormone-Dependent Prostate Cancer,DRUG: SHR3680|DRUG: Bicalutamide,"rPFS, Time from randomisation to radiologically confirmed progressive disease or death due to any cause, Approximately 70 months|OS, Time from randomisation to death due to any cause, Approximately 70 months","Time to prostate specific antigen (PSA) progression, Time from randomisation to the first time of PSA progression according to the criterion of PCGW3, Approximately 70 months|Time to skeletal-related events, Time from randomisation to the first occurrence of a fracture or treatment for the fracture. The skeletal-related event is defined as the occurrence of either pathological or clinical fracture, spinal cord compression, bone-related radiotherapy or surgery, Approximately 70 months|Objective response rate (ORR), The percentage of subjects with measureable disease at baseline who achieved a complete or partial response in their soft tissue disease using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, Approximately 70 months|Time to initiation of a new antineoplastic therapy, Time from randomisation to the initiation of antineoplastic subsequent to the study treatment, Approximately 70 months",,"Jiangsu HengRui Medicine Co., Ltd.",,MALE,"ADULT, OLDER_ADULT",PHASE3,654,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,SHR-3680-III-HSPC,2018-05-30,2023-04-30,2025-04-30,2018-05-09,,2021-03-02,"Complex oncological center - Bourgas, Burgas, Bulgaria|UMHAT 'Deva Maria'. EOOD, Burgas, Bulgaria|MHAT - Dobrich. AD, Dobrich, Bulgaria|MHAT 'Dr. Tota Venkova'. AD, Gabrovo, Bulgaria|Complex Oncological Center - Plovdiv. EOOD, Plovdiv, Bulgaria|MHAT 'Central Onco Hospital'. OOD, Plovdiv, Bulgaria|Acibadem City Clinic Tokuda Hospital Ead, Sofia, Bulgaria|Affiliated Hospital of Hebei University, Baoding, China|Beijing Cancer Hospital, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Peking Union Medical College Hospital, Beijing, China|The third hospital of Peking University, Beijing, China|Tumor Hospital of the Chinese Academy of Medical Sciences, Beijing, China|China Japan Friendship Hospital of Jilin University, Changchun, China|The first hospital of Jilin University, Changchun, China|Hunan Cancer Hospital, Changsha, China|West China Hospital of Sichuan University, Chengdu, China|Army characteristic medical center of the Chinese people's Liberation Army, Chongqing, China|Chongqing Cancer Hospital, Chongqing, China|The First Affiliated Hospital of Army Medical University, Chongqing, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|Sun Yat-Sen hospital of Sun Yat-Sen University, Guangzhou, China|Sun Yat-sen University Cancer Center, Guangzhou, China|The First Affiliated Hospital of Zhejiang University Medicine college, Hangzhou, China|The Second affiliated hospital of zhejiang university medical college, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Zhejiang Province People's Hospital, Hangzhou, China|Anhui Provincial Hospital, Hefei, China|The First Affiliated Hospital of Anhui Medical University, Hefei, China|Qilu Hospital of Shandong University, Jinan, China|Yunnan Provincial Cancer Hospital, Kunming, China|The second hospital of Lanzhou University, Lanzhou, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Gulou Hospital Affiliated to Medical College of Nanjing University, Nanjing, China|Jiangsu Provincial Cancer Hospital, Nanjing, China|Jiangsu Provincial People's Hospital, Nanjing, China|Huadong Hospital of Fudan University, Shanghai, China|Ruijin Hospital, Shanghai, China|Shanghai General Hospital, Shanghai, China|The Cancer Hospital of Fudan University, Shanghai, China|Zhongshan Hospital of Fudan University, Shanghai, China|Liaoning Provincial Cancer Hospital, Shenyang, China|The fourth hospital of Hebei Medical University, Shijia Zhuang, China|The second hospital of Tianjin Medical University, Tianjing, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|Hubei Provincial Cancer Hospital, Wuhan, China|Tongji Hospital, Tongji medical college of HUST, Wuhan, China|Union Hospital, Tongji Medical college of HUST, Wuhan, China|Wuxi People's Hospital, Wuxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|The First Affiliated Hospital of Xiamen University, Xiamen, China|Jiangsu Subei people's Hospital, Yangzhou, China|Henan people's Hospital, Zhengzhou, China|Henan Provincial Cancer Hospital, Zhengzhou, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China|RESEARCH SITE s.r.o., Plzen, Plzeň, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice Olomouc, Pavlov, Czechia|Nemocnice Na Homolce, Praha, Czechia|Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem o.z., Ústí Nad Labem, Czechia|Beskidzkie Centrum Onkologii im.Jana Pawla II, Bielsko-Biala, Bielsko-Biała, Poland|LexMedica Osrodek Badan Klinicznych, Wesoła, Weigla, Poland|KO-MED Centra Kliniczne Biala Podlaska, Biała Podlaska, Poland|Swietokrzyskie Centrum Onkologii, Kielce, Poland|Provita Profamilia, Piotrków Trybunalski, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka, Słupsk, Poland",
